Suppr超能文献

炎症性甲状腺毒症患者中促甲状腺素抗体的检测

Detection of thyroid-stimulating antibody in patients with inflammatory thyrotoxicosis.

作者信息

Mitani Y, Shigemasa C, Kouchi T, Taniguchi S, Ueta Y, Yoshida A, Mashiba H

机构信息

First Department of Internal Medicine, Tottori University School of Medicine, Yonago, Japan.

出版信息

Horm Res. 1992;37(4-5):196-201. doi: 10.1159/000182309.

Abstract

The detection of thyrotropin-binding inhibitory immunoglobulins (TBII) and/or thyroid-stimulating antibody (TSAb) has been reported in some patients with painless thyroiditis (PT) or subacute thyroiditis (SAT). However, its mechanism is unknown. TBII and TSAb measured using cultured FRTL-5 thyroid cells were evaluated in 18 patients with PT, 11 patients with SAT and a patient with SAT-like symptoms. In PT, we detected both TBII and TSAb activities in only 1 patient. This case had first come to our attention with subclinical hypothyroidism and had already had weakly positive TSAb activity (205.9%) 1 year before the present onset of PT. This patient had a transient thyrotoxicosis with a low uptake (24 h) of 123I (4.3%) and 821.0% TSAb activity, and subsequently developed a transient subclinical hypothyroidism. Even after 2 years, she still had positive TSAb activity (382.3%). In SAT, TBII and TSAb activities were not detected during the courses of any patients. A patient with transient thyrotoxicosis, who had a high uptake (30 min) of 99mTc (5.6%) and SAT-like symptoms (painful tenderness on right thyroid lobe and markedly accelerated erythrocyte sedimentation rate), showed positive activities of TBII (34.9%) and TSAb activity (1,366.9%). Histological findings by thyroid needle biopsy performed in the thyrotoxic phase showed coexistence of granulomatous inflammatory changes and hyperplasia with papillary folds of some residual follicular cells.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

在一些无痛性甲状腺炎(PT)或亚急性甲状腺炎(SAT)患者中,已报道检测到促甲状腺素结合抑制性免疫球蛋白(TBII)和/或促甲状腺刺激抗体(TSAb)。然而,其机制尚不清楚。我们对18例PT患者、11例SAT患者和1例有SAT样症状的患者,使用培养的FRTL-5甲状腺细胞检测了TBII和TSAb。在PT患者中,仅1例同时检测到TBII和TSAb活性。该病例最初因亚临床甲状腺功能减退引起我们的注意,在本次PT发病前1年TSAb活性就已呈弱阳性(205.9%)。该患者出现短暂性甲状腺毒症,123I摄取率低(24小时为4.3%),TSAb活性为821.0%,随后发展为短暂性亚临床甲状腺功能减退。即使2年后,她的TSAb活性仍为阳性(382.3%)。在SAT患者中,病程中未检测到TBII和TSAb活性。1例短暂性甲状腺毒症患者,99mTc摄取率高(30分钟为5.6%),有SAT样症状(右甲状腺叶疼痛性压痛和红细胞沉降率明显加快),TBII活性为阳性(34.9%),TSAb活性为1366.9%。在甲状腺毒症期进行的甲状腺细针穿刺活检组织学结果显示,存在肉芽肿性炎症改变和一些残留滤泡细胞的乳头褶皱增生。(摘要截取自250词)

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验